Video

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope in Duarte, CA, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Patients who have relapsed/refractory CLL or SLL and fail ibrutinib (Imbruvica) or venetoclax (Venclexta) have an unmet need for appropriate therapy, says Siddiqi.

The TRANSCEND CLL 004 trial, an open-label, multicenter study, enrolled patients who had received ≥2 lines of therapy, including BTK inhibitors, to receive the investigational CAR T-cell product, lisocabtagene maraleucel (JCAR017). The best overall response rate in 15 evaluable patients was 87%, with 7 patients (47%) achieving complete response.

Eradication of minimal residual disease in the blood was also seen in 67% of patients by day 30, making this an excellent option for this patient population, Siddiqi concludes.

<<< 15th International Conference on Malignant Lymphoma

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD